Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
CTNM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.04 - $22.00
Previous CloseN/A
Volume54.82K
Average Volume (3M)72.08K
Market Cap
$203.64M
Enterprise Value$279.29M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.05
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding19,048,620
10 Day Avg. Volume49,437
30 Day Avg. Volume72,076
Standard Deviation0.14
R-Squared0.00182
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.59
Enterprise Value/Ebitda-7.89
Forecast
1Y Price Target
$31.00Price Target Upside292.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Contineum Therapeutics, Inc. Class A News
PremiumCompany Announcements
Contineum Therapeutics: Q3 2024 Financial OverviewPremiumCompany Announcements
Contineum Therapeutics Announces Corporate Presentation Updates---
Bulls Say, Bears Say
Bulls Say
Financial StrengthA strong cash position of $219M will support multiple clinical readouts.
Market OpportunitiesContineum is targeting large markets with projected opportunities of $24B for MS, $16B for depression, and $4B for IPF by 2030.
Product DifferentiationPIPE-791, an LPA1R antagonist, may have the advantage of once-a-day dosing and higher receptor exposure, potentially leading to better efficacy compared to a phase 3 agent from another company.
Bears Say
---
Options Prices
Currently, No data available
---
Ownership Overview
3.72% Insiders
9.30% Mutual Funds
17.74% Other Institutional Investors
62.48% Public Companies and Individual Investors
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $7.04 and its highest was $22.00 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $203.64M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on Aug 13, 2024. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.348 by -$0.042.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 19,048,620 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.348. Following the earnings report the stock price went up 7.599%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
---
Contineum Therapeutics, Inc. Class A Stock Smart Score
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
---
CTNM Stock 12 Month Forecast
Average Price Target
$31.00
▲(292.41% Upside)
Technical Analysis
Best Analysts Covering CTNM
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-45.24%
assigned a buy rating 2 months ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -45.24% per trade.
---